Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Post by Smokey1958on Apr 18, 2021 8:34pm
340 Views
Post# 33019892

Judging By the Tweet

Judging By the TweetNot much cryptic in the tweet as it certainly appearsTHRM isn't banking on HC approval anytime soon. While that's disappointing it's great to know they are forging ahead. In the meantime the opportunities look far more promising in terms of timing and potential revenues by thinking outside of Canada.

They have now been "patiently" waiting since February 26th for HC approval just to carry out the testing. Sorry, but there is no excuse for that ....especially as the current covid situation evolves here. Re-testing of AcuVid is likely already in the works in Brazil and clearly THRM is looking toward putting together a "resume" of testing results to move toward CE, FDA and EUA approval.

I thought that with the same 9 rapid, antigen point of care tests under review for weeks that HC would be moving much more quickly. Glad to see Rob and team are still modifying and changing the direction as required. Shouldn't be much longer to wait.

Looking forward to the next few weeks,

GLTE!!!
<< Previous
Bullboard Posts
Next >>